Roche's Herceptin given by subcutaneous injection offers greater convenience ... PipelineReview.com (press release) Roche are also investigating the use of MabThera (rituximab) for subcutaneous injection in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. MabThera for subcutaneous injection is not currently licensed or approved in any market. |
